IP Verse

Pharmaceutical Composition And Administrations Thereof - EP2464337

The patent EP2464337 was granted to Vertex Pharmaceuticals on Jun 26, 2024. The application was originally filed on Feb 18, 2010 under application number EP10708442A. The patent is currently recorded with a legal status of "Patent Maintained As Amended".

EP2464337

VERTEX PHARMACEUTICALS
Application Number
EP10708442A
Filing Date
Feb 18, 2010
Status
Patent Maintained As Amended
May 24, 2024
Grant Date
Jun 26, 2024
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

TEVA PHARMACEUTICALSOct 7, 2019D YOUNGADMISSIBLE

Patent Citations (9) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication NumberPublication Link
DESCRIPTIONUS2004006237
DESCRIPTIONWO2007079139
INTERNATIONAL-SEARCH-REPORTWO2007079139
INTERNATIONAL-SEARCH-REPORTWO2009023509
INTERNATIONAL-SEARCH-REPORTWO2010019239
OPPOSITIONWO2007079139
OPPOSITIONWO2008080167
OPPOSITIONWO2010019239
OPPOSITIONWO2011019413

Non-Patent Literature (NPL) Citations (6) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference TextLink
OPPOSITION- "cellelose microcrystaline", RAYMOND C ROWE et al., Handbook of pharmaceutical excipients, (20090731), pages 129-133,185-188,206-208,376-378,404,651 - 653, XP055651710-
OPPOSITION- "Food's journey through the digestive system", (20191001), URL: https://www.sciencelearn.org.nz/resources/1849-food-s-journey-through-the-digestive- system, XP055651703-
OPPOSITION- "Lumacaftor", chemspider, Database accession no. 17611836, XP055651669-
OPPOSITION- "Pharmaceutics - The science of dosage form design", Edt. M E Aulton, Churchill Livingston, (19980000), pages 304 - 305, XP055651697-
OPPOSITION- "Vertex Pharmaceuticals Initiates Phase 2 Development for CFTR Corrector VX-809 in Patients with Cystic Fibrosis", Vertex Press Release, (20090325), XP055651674-
OPPOSITION- "Vertex Pharmaceuticals Initiates Phase 3 Registration Program for VX-770, an Oral CFTR Potentiator Targeting the Defective Protein Responsible for Cystic Fibrosis", Vertex Press Release, (20090527), XP002528469-

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents